WO2025114760 - TYK2 INHIBITORS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/114760
Publication Date
05.06.2025
International Application No.
PCT/IB2024/000679
International Filing Date
26.11.2024
Title **
[English]
TYK2 INHIBITORS AND USES THEREOF
[French]
INHIBITEURS DE TYK2 ET LEURS UTILISATIONS
Applicants **
SUDO BIOSCIENCES LIMITED
Inventors
PANDEY, Anjali
THAKKAR, Mahesh
DURAISWAMY, Athisayamani, Jeyaraj
MADHYASTHA, Naveena
GOSWAMI, Rajeev
Priority Data
63/604,078
29.11.2023
US
63/659,710
13.06.2024
US
63/677,846
31.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6260 | |
| EPO | Filing, Examination, Granting | 83249 | |
| Japan | Filing, Examination, Granting | 4440 | |
| South Korea | Filing, Examination, Granting | 6790 | |
| USA | Filing, Examination, Granting | 21540 |
Total:
122,279
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of TYK2 activity.[French]
L'invention concerne des composés qui sont des inhibiteurs de TYK2, des procédés de fabrication de tels composés, des compositions pharmaceutiques et des médicaments comprenant de tels composés, et des méthodes d'utilisation de tels composés dans le traitement de pathologies, de maladies ou de troubles qui bénéficieraient de la modulation de l'activité de TYK2.